iCAD Announces Schedule of Events and Featured Image Analysis Solutions for Breast, Prostate and Colon Cancer Detection at the 2009 RSNA

Nashua, NH - November 24, 2009

iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announces its schedule of events at the 95th annual meeting of the Radiological Society of North America (RSNA) in Chicago, from November 29 through December 4, 2009.

"iCAD is at the forefront of helping radiology professionals incorporate advanced image analysis and workflow solutions to streamline their processes and to improve patient care," said Ken Ferry, President and CEO of iCAD. "At RSNA this year, we will feature the most cutting-edge technologies for computer-aided detection applied to digital mammography, breast and prostate MRI and CT Colonography*. It promises to be a big event for showcasing our technology and educational initiatives around incorporating image analysis and workflow improvements into both hospitals and free-standing imaging centers."

Important presentations and conference sessions discussing the use of computer-aided detection (CAD) and other advanced image analysis solutions for the early detection of cancer include:

- **Sunday, November 29**, iCAD will co-host the Industrial Liaison Board of the International Prostate MRI Working Group, in conjunction with AdMeTech Foundation. Modeled on the Breast Cancer MRI Working Group, this group fosters dialogue between academia, leading physicians, prostate cancer advocacy groups and industry to expedite the advancement of MRI technologies and their use in the diagnosis and management of prostate cancer.

- **Monday, November 30 at 3:20 PM in room E353C**, "Performance of Computer-Aided Detection with Computed Tomographic Colonography in a Large Clinical Trial with 19 Readers and 100 Patients," presented by Abraham H. Dachman, M.D., from The University of Chicago Hospital. The information will also be included at an educational exhibit during RSNA.


In addition, iCAD will host a non-RSNA satellite symposium on: For more information please visit www.admetech.org.

- **Tuesday, December 1, 2009 at 7 AM at the Hyatt Regency in Chicago, room CC24BC.** The session will review how quantitative image analysis (CAD) and MRI play an integral role in prostate cancer programs including pre-biopsy guidance, treatment planning, active surveillance and therapy response monitoring. Presentations will be given by leading clinical experts, Dr. François Cornud, Diagnostic and Interventional Radiologist at the Centre d’Imagerie Tourville and Dr. Russell Low, Medical Director at Sharp and Children’s MRI Center. Areas of focus will include how DCE-MRI in conjunction with other MRI imaging techniques can improve the sensitivity and specificity of prostate cancer localization and detection as compared to current imaging practices. Specific case examples will be shared, including how DCE-MRI and CAD support improved treatment planning for patients undergoing Cyberknife therapy.

To register for the symposium, please call iCAD at 1-866-280-2239 ext. 7943 or visit www.icadmed.com.
iCAD’s advanced imaging technologies will be featured at their booth, #6224, South Building, Hall A, located at McCormick Place.

iCAD’s MRI technologies featured at RSNA include:

- **CADvue® MRI review software and analysis solution** for maximum functionality facilitating the analysis of all available time points (ATP) colorized images and quantitative data. CADvue allows the user to create standard and customized reports that enable the radiologist to communicate time-sensitive breast and prostate MRI study results to referring physicians.

- **VividLook™ MRI prostate analysis solution**, provides more diagnostic information by utilizing all time points, creating colorized images based on signal changes defined by tumor physiology. This post-processing software package is designed to provide a reliable means of visualizing the presence and pattern of contrast induced enhancement of MRI images in the prostate, helping radiologists distinguish benign from malignant lesions.

- **SpectraLook™ Computer-Aided Detection (CAD) technology**, designed to assist radiologists in distinguishing potential cancers in the breast as part of their overall analysis of the MRI procedure results. It provides radiologists with more diagnostic information by creating colorized images based on direct signal changes due to contrast agent influx and efflux rates using key physiological measures that relate to tumor physiology.

- **PrecisionPoint® interventional planning solution for breast MRI**, provides radiologists with an automatic calculation of the location and depth of a targeted region of interest making biopsies easier, faster, and more reliable for both grid and post and pillar methods.

For digital mammography, iCAD will highlight:

- **SecondLook® Digital CAD system**, which offers unique compatibility with industry leading Full-Field Digital Mammography (FFDM) solutions – both Digital Radiography (DR) and Computed Radiography (CR).

- **TotalLook MammoAdvantage® (TLMA)**, the state-of-the-art film digitizing solution that is an integral part of the digital mammography workflow. iCAD’s second generation mammography-specific digitizer, TLMA, offers improved image quality, enhanced image customization options and workflow efficiency benefits to centers moving from analog to digital mammography.

For CT CAD Solution, iCAD will demonstrate:

- **VeraLook™**, iCAD’s revolutionary CAD solution for virtual colonoscopy (CTC). This solution is designed to aid radiologists in the detection of polyps during their review of CTC exams. Clinical evidence suggests that CAD for CTC will enhance radiologist effectiveness in interpreting CTC studies. VeraLook will be demonstrated on a Viatronix V3D and the TeraRecon AQI workstations.*

*For sale outside the US only

About iCAD, Inc.

iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 3,200 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer. For more information, call (877) iCADnow or visit [www.icadmed.com](http://www.icadmed.com).

For iCAD, contact Darlene Depta-Hicks at 603-882-5200 x7944, or via email at ddeptula@icadmed.com

For Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn & Associates at 212-838-3777 x6604 or via email at afields@lhai.com

For media inquiries, contact Liza Heapes of MS&L PR at 617-369-8787 or via e-mail at liza.heapes@mslworldwide.com

**NOTE TO EDITORS, IMAGES AVAILABLE**

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:

Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological...
supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "anticipate", "likely", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.